RecruitingPhase 2NCT06622941
Study to ONO-4538 in Patients With Rhabdoid Tumor
Studying Atypical teratoid rhabdoid tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ono Pharmaceutical Co. Ltd
- Principal Investigator
- Project LeaderOno Pharmaceutical Co. Ltd
- Intervention
- ONO-4538(drug)
- Enrollment
- 23 enrolled
- Eligibility
- 1 years · All sexes
- Timeline
- 2024 – 2030
Study locations (5)
- Nagoya University Hospital, Nagoya, Aichi-ken, Japan
- Hokkaido University Hospital, Sapporo, Hokkaido, Japan
- Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyōgo, Japan
- Osaka City General Hospital, Osaka, Osaka, Japan
- National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06622941 on ClinicalTrials.govOther trials for Atypical teratoid rhabdoid tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06465199Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and SarcomasMilton S. Hershey Medical Center
- RECRUITINGEARLY PHASE1NCT07017816A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.Children's National Research Institute
- RECRUITINGPHASE1NCT06193759Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)Children's National Research Institute
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05407441Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsSusan Chi, MD
- RECRUITINGPHASE1NCT05835687Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS TumorsSt. Jude Children's Research Hospital
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05286801Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGPHASE2NCT06853080Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid TumorsTaipei Medical University
- ACTIVE NOT RECRUITINGPHASE2NCT04416568Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative CancersDana-Farber Cancer Institute